Status: Recruiting
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.
Participants needed: 38
Trial details
Phase: Phase 2Age: 2-18Biological sex: AllType: InterventionalSponsor: Shandong Cancer Hospital and InstituteUpdated: Feb 10, 2025Locations: 1
Eligibility criteria
Histologically or cytologically confirmed rhabdomyosarcoma (RMS). [+11]
Received any of the following treatments within 2 weeks before treatment: radiot... [+14]